S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)

3 Stocks Rising On Stellar Earnings And Revenue Growth

Wednesday, April 14, 2021 | Kate Stalter
3 Stocks Rising On Stellar Earnings And Revenue Growth

One hallmark of a growth stock is strong quarterly and annual earnings, and that’s something that DR Horton (NYSE: DHI), Boise Cascade (NYSE: BCC) and Quest Diagnostics (NYSE: DGX) have in common. 

Although these three stocks hail from diverse industries, all are good examples of run-ups on the heels of solid earnings growth. 

While it’s certainly common to see newer stocks race higher without any history of profitability, the stocks that gain a higher share of institutional ownership tend to be those with quarterly or yearly earnings. 

Those institutional buyers, such as mutual funds, hedge funds, banks, insurance companies and university endowments, research their purchases carefully and don’t just buy on a “hunch.” Earnings growth is one key fundamental metric they analyze.

For a retail investor looking for a stock with promise, here are some items to watch for: 

  • Earnings growth of at least 18% vs. the year-earlier quarter
  • Annual earnings growth of at least 25% per year
  • Revenue up 25% or more recently, or with an accelerating growth rate in recent quarters
  • Return on equity of at least 17%

These are characteristics of some of the biggest winning stocks over the past decades. 

Don’t worry if a stock meeting these criteria isn’t from a hot sector, or a meme stock, or some big familiar name. Plenty of stocks you’ve never heard of are unsung heroes. 

Homebuilder DR Horton grew quarterly earnings at rates of 29% or higher in each of the past five quarters, with growth accelerating in the past two. On a yearly basis, net income grew 31.73%. 

Although this can easily be attributed to the home construction boom, the reason for the growth actually doesn’t matter, when you’re looking at the fundamental data. 

Revenue growth accelerated in the past three quarters, with a year-over-year increase of 48% most recently, to $5.933 billion. Annual revenue trended higher on a three-year basis. The company has a return on equity of 21%.

DR Horton’s price appreciation reflects institutional confidence in the stock. It’s up 35.43% year-to-date and 143.05% over 12 months. Part of that growth is due to mutual fund ownership, which rose over the past three quarters. 

Shares closed Wednesday at $92.83, down $0.31, o 0.33%.

Another company breaking out with the housing boom is Boise Cascade, which manufactures engineered wood products for the construction industry. Earnings grew at double- or triple-digit rates in each of the past five quarters. The three-year earnings growth rate is 28.25%.

Revenue has been growing during that same time frame, with growth of 25% and 34% over the past two quarters. The most recent quarterly revenue was $1.472 billion. 

The return on equity is 31%, illustrating efficient use of shareholder investment.

Boise Cascade has also seen a rise in institutional investment in the past three quarters. The stock returned 36.21% year-to-date and 143.32% over the past year. Shares closed Wednesday at $65.92, up $0.91, or 1.40%. 

Quest Diagnostics doesn’t have the stellar return of stocks in the homebuilding industry, but it’s been a solid performer over the past year, with a return of 51.21%. It’s up 8.73% so far in 2021. 

In the past two quarters, earnings rose 145% and 168%, coming in at $4.48 per share most recently. 

The three-year net income growth rate is 22.84%. 

Revenue grew 42% and 56%, rising to $3 billion in the quarter ended in December. 

Here, too, institutional ownership has been on the rise, contributing to price appreciation. 

Return on equity is 25%. 

What’s been driving growth? 

Quest operates a network of independent diagnostic testing centers throughout the U.S. The company is benefiting from increased diagnostic tests, including those to determine custom therapies, a growing market. 

Analysts also believe hospital-based labs will continue outsourcing a growing number of tests, which will also help Quest. 

Quest shares closed Wednesday at $127.36, down $1.03, or 0.80%.

D.R. Horton is a part of the Entrepreneur Index, which tracks some of the largest publicly traded companies founded and run by entrepreneurs.

Should you invest $1,000 in D.R. Horton right now?

Before you consider D.R. Horton, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and D.R. Horton wasn't on the list.

While D.R. Horton currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
D.R. Horton (DHI)3.4$87.04-0.3%0.92%8.73Buy$103.65
Boise Cascade (BCC)2.1$54.23-1.5%0.74%3.70Hold$56.20
Quest Diagnostics (DGX)2.7$153.09-0.3%1.62%9.13Buy$157.78
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.